Immediate Impact
60 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021
2025 Standout
Works of Philip Vutien being referenced
Hepatocellular Carcinoma Risk Declines but Remains High Enough for Screening in the First 7 Years After Hepatitis C Virus Cure With Direct-Acting Antivirals in Patients With Cirrhosis or High Fibrosis-4 Score
2022
Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Philip Vutien | 412 | 410 | 58 | 50 | 535 | |
| Vicki Wing‐Ki Hui | 375 | 476 | 43 | 40 | 633 | |
| Jimmy Che‐To Lai | 320 | 416 | 43 | 48 | 540 | |
| José Ignacio Fortea | 374 | 395 | 96 | 44 | 558 | |
| Fernando Ramalho | 369 | 363 | 67 | 44 | 511 | |
| Ana de Lourdes Candolo Martinelli | 360 | 414 | 82 | 50 | 581 | |
| Anna Rutherford | 351 | 286 | 131 | 24 | 553 | |
| Ricardo Franco | 363 | 347 | 40 | 43 | 495 | |
| Valentina Cossiga | 230 | 298 | 66 | 39 | 464 | |
| Liana Codés | 322 | 307 | 105 | 43 | 492 | |
| Faisal Abaalkhail | 335 | 382 | 164 | 55 | 568 |
All Works
Login with ORCID to disown or claim papers
Loading papers...